Accomplished in vivo pharmacologist with extensive experience in biotechnology industries, focused on discovery and development of siRNA, protein and gene therapy for Neurodegenerative and rare diseases. Proven leadership in building platform capabilities for in-vivo pharmacology and directing high-performance project team. Scientific leader in animal models for PK/PD/Efficacy/ studies, animal disease model development and characterization, and pre-clinical IND-enabling studies. Highly valued internal and external collaborator with effective oral and written communications skills; team player with strong organizational and interpersonal skills. Experienced with CRO and academic collaborations.
Qingmin Chen is an accomplished in vivo pharmacologist with 27.9 years of experience in the biotechnology industry. She has expertise in in vivo, drug discovery, animal models, and neuroscience. Based in the United States, Qingmin has a proven track record in building platform capabilities for in-vivo pharmacology and leading high-performance projects. She is highly valued in both internal and external collaborations and has excellent communication skills. Qingmin has held various senior positions at Atalanta Therapeutics and Voyager Therapeutics, Inc., gaining valuable experience in research and analytics.
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager’s TRACER AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Pfizer Inc., Novartis and Neurocrine Biosciences as well as multiple programs in Voyager’s own pipeline. Voyager’s pipeline includes preclinical programs in Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS), each with validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit www.voyagertherapeutics.com.Recognizing that we can expand on the experience, innovation, and outcomes that propel our efforts by working together, we actively seek diverse views. If you’re someone who wants to make discoveries that change the landscape of medicine for patients, we want you on our team!
Synageva BioPharma is a biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines for people living with rare diseases of high unmet medical need. We are passionate about our commitment to improving their lives and those of their families for generations to come. Our experienced team has helped bring several life-saving therapies for diseases that were once considered too rare for development treatments. We believe that every patient deserves treatment options, no matter how rare their disease. We believe that when it comes to delivering innovative therapies, Every Second Counts.
To those who say “impossible, impractical, unrealistic,” we say: “CHALLENGE ACCEPTED.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring RNAi-based medicines to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Alnylam is turning scientific possibility into reality - in 2018, the FDA and EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. We now have four additional medicines on the market. Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of 1,900+ people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer 3 years in a row ('19-'21), a Boston Globe Top Place to Work 8x in a row ('15-'21) and Fast Company's #1 Best Workplace for Innovators ('22 We are based in Cambridge, U.S., with offices throughout Europe, Asia, and South America. We invite you to connect with us by following us on LinkedIn, Facebook (@AlnylamPharma) Twitter (@Alnylam), Instagram (@AlnylamPharma) and YouTube. See our community guidelines: https://bit.ly/2FcRhJy.
Small Animal Surgeries
We found 2 Qingmin chen's email addresses
We found 1 Qingmin chen's phone numbers
Qingmin chen's social media include: Linkedin,
Qingmin chen works for Atalanta Therapeutics
Qingmin chen's role in Atalanta Therapeutics is Vice President Head Of In Vivo Pharmacology
Qingmin chen works in the industry of
Qingmin chen's colleagues are
Qingmin chen's latest job experience is Vice President Head Of In Vivo Pharmacology at Atalanta Therapeutics
Qingmin chen's latest education in University of Arizona College of Medicine – Tucson